155 related articles for article (PubMed ID: 38044419)
21. Pharmacokinetics and metabolism of [
Mancel V; Mathy FX; Boulanger P; English S; Croft M; Kenney C; Knott T; Stockis A; Bani M
Xenobiotica; 2017 Aug; 47(8):705-718. PubMed ID: 27489076
[TBL] [Abstract][Full Text] [Related]
22. Metabolism, pharmacokinetics, and excretion of a nonpeptidic substance P receptor antagonist, ezlopitant, in normal healthy male volunteers: characterization of polar metabolites by chemical derivatization with dansyl chloride.
Prakash C; O'Donnell J; Khojasteh-Bakht SC
Drug Metab Dispos; 2007 Jul; 35(7):1071-80. PubMed ID: 17431029
[TBL] [Abstract][Full Text] [Related]
23. A Phase I, Open-Label, Mass Balance Study of [
Cheng Y; Wang X; Liu L; Silva J; Thomas M; Li Y
Eur J Drug Metab Pharmacokinet; 2024 May; 49(3):355-365. PubMed ID: 38521893
[TBL] [Abstract][Full Text] [Related]
24. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.
Stopfer P; Marzin K; Narjes H; Gansser D; Shahidi M; Uttereuther-Fischer M; Ebner T
Cancer Chemother Pharmacol; 2012 Apr; 69(4):1051-61. PubMed ID: 22200729
[TBL] [Abstract][Full Text] [Related]
25. Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans.
Taavitsainen P; Prien O; Kähkönen M; Niehues M; Korjamo T; Denner K; Nykänen P; Vuorela A; Jungmann NA; von Bühler CJ; Koskinen M; Zurth C; Gieschen H
Drug Metab Dispos; 2021 Jun; 49(6):420-433. PubMed ID: 33785516
[TBL] [Abstract][Full Text] [Related]
26. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans.
Prakash C; Kamel A; Gummerus J; Wilner K
Drug Metab Dispos; 1997 Jul; 25(7):863-72. PubMed ID: 9224781
[TBL] [Abstract][Full Text] [Related]
27. Open-label, single-center, phase I trial to investigate the mass balance and absolute bioavailability of the highly selective oral MET inhibitor tepotinib in healthy volunteers.
Johne A; Scheible H; Becker A; van Lier JJ; Wolna P; Meyring M
Invest New Drugs; 2020 Oct; 38(5):1507-1519. PubMed ID: 32221754
[TBL] [Abstract][Full Text] [Related]
28. Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
Vincent SH; Reed JR; Bergman AJ; Elmore CS; Zhu B; Xu S; Ebel D; Larson P; Zeng W; Chen L; Dilzer S; Lasseter K; Gottesdiener K; Wagner JA; Herman GA
Drug Metab Dispos; 2007 Apr; 35(4):533-8. PubMed ID: 17220239
[TBL] [Abstract][Full Text] [Related]
29. Mass balance and metabolism of Z-215, a novel proton pump inhibitor, in healthy volunteers.
Toda R; Miyagawa T; Masuda Y; Hoshino Y; Yoshii K; Hirayama M; Shibuya M; Kawabata Y
Xenobiotica; 2018 Oct; 48(10):1006-1020. PubMed ID: 29092680
[TBL] [Abstract][Full Text] [Related]
30. Absorption, distribution, metabolism, and excretion (ADME) of ¹⁴C-sonidegib (LDE225) in healthy volunteers.
Zollinger M; Lozac'h F; Hurh E; Emotte C; Bauly H; Swart P
Cancer Chemother Pharmacol; 2014 Jul; 74(1):63-75. PubMed ID: 24817600
[TBL] [Abstract][Full Text] [Related]
31. Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study.
Morice A; Smith JA; McGarvey L; Birring SS; Parker SM; Turner A; Hummel T; Gashaw I; Fels L; Klein S; Francke K; Friedrich C
Eur Respir J; 2021 Nov; 58(5):. PubMed ID: 33986030
[TBL] [Abstract][Full Text] [Related]
32. Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [
Gerisch M; Schwarz T; Lang D; Rohde G; Reif S; Genvresse I; Reschke S; van der Mey D; Granvil C
Cancer Chemother Pharmacol; 2017 Sep; 80(3):535-544. PubMed ID: 28714036
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.
Nussbaum JC; Hussain A; Ma B; Min KC; Chen Q; Tomek C; Iwamoto M; Stoch SA
Pharmacol Res Perspect; 2022 Feb; 10(1):e00924. PubMed ID: 35106949
[TBL] [Abstract][Full Text] [Related]
34. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
[TBL] [Abstract][Full Text] [Related]
35. Mass balance and metabolism of the antimalarial pyronaridine in healthy volunteers.
Morris CA; Dueker SR; Lohstroh PN; Wang LQ; Fang XP; Jung D; Lopez-Lazaro L; Baker M; Duparc S; Borghini-Fuhrer I; Pokorny R; Shin JS; Fleckenstein L
Eur J Drug Metab Pharmacokinet; 2015 Mar; 40(1):75-86. PubMed ID: 24590312
[TBL] [Abstract][Full Text] [Related]
36. Absorption, metabolism, excretion, and safety of [
Zhou C; Xie L; Liu W; Zhang L; Zhou S; Wang L; Chen J; Li H; Zhao Y; Zhu B; Ding S; Zhang C; Shao F
Ann Transl Med; 2021 May; 9(10):867. PubMed ID: 34164501
[TBL] [Abstract][Full Text] [Related]
37. Eliapixant is a selective P2X3 receptor antagonist for the treatment of disorders associated with hypersensitive nerve fibers.
Davenport AJ; Neagoe I; Bräuer N; Koch M; Rotgeri A; Nagel J; Laux-Biehlmann A; Machet F; Coelho AM; Boyce S; Carty N; Gemkow MJ; Hess SD; Zollner TM; Fischer OM
Sci Rep; 2021 Oct; 11(1):19877. PubMed ID: 34615939
[TBL] [Abstract][Full Text] [Related]
38. Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil.
Muirhead GJ; Rance DJ; Walker DK; Wastall P
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):13S-20S. PubMed ID: 11879255
[TBL] [Abstract][Full Text] [Related]
39. Disposition and metabolism of 14C-rifapentine in healthy volunteers.
Reith K; Keung A; Toren PC; Cheng L; Eller MG; Weir SJ
Drug Metab Dispos; 1998 Aug; 26(8):732-8. PubMed ID: 9698286
[TBL] [Abstract][Full Text] [Related]
40. Biotransformation Pathways and Metabolite Profiles of Oral [
Pusalkar S; Zhou X; Li Y; Cohen L; Yang JJ; Balani SK; Xia C; Shyu WC; Lu C; Venkatakrishnan K; Chowdhury SK
Drug Metab Dispos; 2020 Mar; 48(3):217-229. PubMed ID: 31911485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
